![](https://static.youtibao.com/asksite/comm/h5/images/m_q_title.png)
[单选题]
卡瑞利珠+阿帕替尼“双艾”联合方案用于治疗晚期复发TNBC的总人群mPFS如何()
A.4.0
B.3.8
C.3.9
D.3
![](https://static.youtibao.com/asksite/comm/h5/images/m_q_a.png)
D、3
![](https://static.youtibao.com/asksite/comm/h5/images/solist_ts.png)
A.4.0
B.3.8
C.3.9
D.3
D、3
A.卡瑞利珠单抗200mgQ2W+阿帕替尼500mgQD
B.卡瑞利珠单抗200mgQ3W+阿帕替尼250mgQD
C.卡瑞利珠单抗200mgQ3W+阿帕替尼500mgQD
D.卡瑞利珠单抗200mgQ2W+阿帕替尼250mgQD
A.一线:卡瑞利珠单抗+紫杉醇+顺铂
B.一线:卡瑞利珠单抗+紫杉醇脂质体+阿帕替尼+顺铂
C.二线:卡瑞利珠单抗单药
D.二线:卡瑞利珠单抗+阿帕替尼
A.50%,98.3%
B.14.7%,98.3%
C.50%,93.8%
D.14.7%,93.8%
A.卡瑞利珠单抗+阿帕替尼,Q2W
B.卡瑞利珠单抗+卡铂+培美曲塞,Q2W
C.卡瑞利珠单抗+顺铂+培美曲塞,Q3W
D.卡瑞利珠单抗+卡铂+培美曲塞,Q3W